The economic burden and managed care implications of chronic inflammatory demyelinating polyneuropathy

Am J Manag Care. 2018 Sep;24(17 Suppl):S380-S384.


Chronic inflammatory demyelinating polyneuropathy (CIDP) is a symmetric demyelinating peripheral neuropathy with either a progressive or relapsing remitting course. CIDP is both debilitating and degenerative, leaving patients with functional impairment due to nerve damage in their extremities. Along with its medical burden, CIDP has a significant economic impact, with disease-related expenses and the often fairly high costs related to the immune therapies used to treat the disease. Costs for patients with this disorder often exceed those of other immune-mediated neuromuscular diseases. For these reasons, it is necessary for clinicians to better determine optimal long-term treatment strategies for patients with CIDP that are designed to address both the clinical and economic burden of its management and improve patient outcomes and quality of life.

Publication types

  • Review

MeSH terms

  • Cost Control
  • Cost of Illness*
  • Health Care Costs
  • Humans
  • Managed Care Programs* / economics
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / economics*
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / therapy